TNGX · Tango Therapeutics, Inc.
$23.08
-0.16 (-0.69%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$4.20B
Shares
168.61M
Volume · Oct 5
1.94M
Avg daily vol (3M)
2.59M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$23.08
Open$23.29
Day$22.25–23.56
52W close$6.91–32.90
Avg vol 30d2.9M
Short int41.9M · 24.8% float · 18.8d
Short vol71%
DataSep 2020–Oct 2026
Filing10-Q · Aug 11
Up next
filed Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$53.81M
Trailing 12 months
Net income (TTM)
−$123.72M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
-253.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.01B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+35.6%
Year over year · more shares
Price change (1Y)
+202.2%
Trailing year
Short interest
24.8%
Latest settlement · 18.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Neutral
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+10%
above
Price vs 50-day avg
−7%
below
RSI (14)
44
neutral
MACD trend
Positive
52-week position
62%
mid-range
Momentum
relative strength
1-month return
+2%
trailing
6-month return
−4%
trailing
YTD return
+161%
this year
Relative strength
−16%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $25 › 200d $21 — 50d above 200d
Institutional flow
Accumulating
+27% holders QoQ · +77 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
24.83% of float · ▼ -1.8% MoM · 18.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
248 holders — near 3-yr high, broad support
Squeeze score
70
elevated · 0–100
Fundamentals
Revenue growth
+48%
Y/Y
EPS growth
+27%
Y/Y
Free cash flow
$-139.9M
Quant / Vol
risk profile
Volatility
101%
annualized · 1-yr
Max drawdown
−34%
past year
ATR
6.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+10%
Bullish
Price vs 50-day avg
−7%
Bearish
RSI (14)
44
Neutral
MACD trend
Positive
Bullish
52-week position
62%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $25 › 200d $21 — 50d above 200d
Institutional flow
Accumulating
+27% holders QoQ · +77 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
24.83% of float · ▼ -1.8% MoM · 18.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
248 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $7
Now $23 · 62%
Range high $33
vs 200-day avg +10%
vs 50-day avg -7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Discovery direct program expenses | $2.41M | the three months ended June 30, 2026 filing | — |
| Facilities and other related expenses | $4.55M | the three months ended June 30, 2026 filing | — |
| Personnel-related expenses | $13.98M | the three months ended June 30, 2026 filing | — |
| TNG260 direct program expenses | $1.34M | the three months ended June 30, 2026 filing | — |
| TNG456 direct program expenses | $2.45M | the three months ended June 30, 2026 filing | — |
| TNG908 direct program expenses | $60K | the three months ended June 30, 2026 filing | — |
| TNG961 direct program expenses | $59K | the three months ended June 30, 2026 filing | — |
| vopimetostat direct program expenses | $12.35M | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TNGX
this stock
Tango Therapeutics, Inc.
|
$4.20B | +160.5% | +48.3% | — | 24.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TNGX | -5.0% | +2.5% | -4.1% | -7.5% | +160.5% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -6.2% | +1.9% | -15.6% | -9.1% | +146.9% |